Aligos Therapeutics

Aligos Therapeutics is dedicated to developing targeted therapies for metabolic dysfunction-associated steatohepatitis (MASH) and viral diseases. The company leverages small molecule and oligonucleotide platforms to identify and develop drug candidates targeting clinically validated mechanisms of action. With offices in South San Francisco, California; Leuven, Belgium; and Shanghai, China, Aligos Therapeutics operates on a global scale. The company has a pipeline of potentially best-in-class drug candidates for chronic liver diseases and viral infections, including MASH, chronic hepatitis B (CHB), and coronavirus. Aligos Therapeutics has received over $12 million in funding from the NIH and NIAID’s AViDD Centers for Pathogens of Pandemic Concern program through the MAVDA consortium and a recently awarded NIAID Contract. The company maintains a hybrid work philosophy that supports both face-to-face collaboration and remote work options. Employees benefit from a comprehensive range of benefits, including medical, dental, and vision insurance, paid holidays, year-end holiday closure, paid time off, paid sick leave, new parent leave, pension plan support, 401(k) with employer match, employee stock purchase plan, equity compensation, transit and parking FSA, company car for eligible employees, career development opportunities, meal subsidy, and a dog-friendly workplace. Aligos Therapeutics fosters a science-first, data-driven culture in a highly-collaborative, fast-paced environment and is committed to diversity, equity, and inclusion in its initiatives. The company has presented clinical data at various scientific conferences, including ESCMID, APASL, HEP DART, AASLD, SITC, and EASL. Aligos Therapeutics aims to become a world leader in the development of targeted therapies for MASH and viral diseases to address important unmet medical needs.